PromicsEdge DNAmind PGx vs Conventional PGx: Guidance for Practitioners

PromicsEdge offers two distinct pharmacogenomics (PGx) reports that are not interchangeable: the Medication Check (PGx) Report (the conventional, guideline-driven PGx report), which is clinically validated, and the DNAmind PGx Report, which is an exploratory, mental-health-focused report. This article explains how they differ, when each is appropriate, and how to position them responsibly.

Executive summary

• The Medication Check (PGx) Report (conventional PGx) is clinically validated and guideline-driven, intended to support medication selection and dosing discussions.
• The DNAmind PGx Report is an exploratory, mental-health-focused report designed to mirror popular psychiatric PGx reports (e.g., "Genomind"-style reports).
• The DNAmind PGx Report is not validated by our science or R&D teams and includes low-evidence and hypothetical associations.
• The two reports are not interchangeable and should not be positioned as such.

Scientific validation and governance

Medication Check (PGx) Report

• Fully reviewed and validated by our science and R&D teams.
• Conservative by design, prioritizing reproducibility and clinical reliability.
• Built to align with real-world medical decision-making workflows.

DNAmind PGx Report

• Explicitly not validated by our science and R&D teams.
• Includes extrapolated, hypothesis-based, and non-authoritative interpretations.
• Designed for educational insight and discussion, not clinical action.

Clinical implication: Rely only on the Medication Check (PGx) Report when clinical confidence and defensibility are required.

Evidence standards

Medication Check (PGx) Report

• Includes only variants with moderate to high levels of evidence.
• Draws from established pharmacogenomic authorities, including CPIC, PharmGKB, and FDA-recognized and DPWG guidelines.
• All recommendations are traceable to recognized clinical guidance.

DNAmind PGx Report

• Additionally includes low-evidence associations, non-replicated findings, and mechanistic or pathway-based hypotheses.
• Some variants are included for pattern recognition or theoretical relevance rather than clinical consensus.

Clinical implication: DNAmind PGx findings should never be treated as clinical and should not independently guide medication changes.

Clinical scope and focus

Medication Check (PGx) Report

• Broad, cross-disciplinary medication coverage, including cardiovascular agents, gastrointestinal medications, immunology and oncology therapies, pain management, and select psychiatric drugs with strong evidence bases.

DNAmind PGx Report

• Narrower but deeper focus on mental health and neuropsychiatry, including antidepressants (SSRIs, SNRIs, TCAs, MAOIs), antipsychotics, ADHD medications, anxiolytics and hypnotics, and mood stabilizers.
• Includes neurotransmitter receptors, transporters, and side-effect susceptibility genes often excluded from conservative PGx panels.

Clinical implication: The DNAmind PGx Report may surface discussion-worthy signals in psychiatry but sacrifices evidentiary rigor for breadth.

Intended use in practice

Appropriate uses

Medication Check (PGx) Report

• Medication selection support
• Dose adjustment discussions
• Risk stratification grounded in consensus guidelines
• Documentation-friendly, defensible clinical conversations

DNAmind PGx Report

• Educational exploration with informed clients
• Contextualizing prior medication responses
• Generating hypotheses for further evaluation or confirmatory testing
• Practitioner-guided discussion only

Inappropriate uses (DNAmind PGx Report)

• Initiating, discontinuing, or modifying medications
• Replacing validated PGx testing
• Standalone clinical decision-making

Practitioner positioning and best practices

To use these reports responsibly:

• Clearly explain the distinction between the two reports to clients.
• Frame DNAmind PGx results as informational and hypothetical.
• Use the Medication Check (PGx) Report when documentation, liability, or clinical certainty matters.
• Avoid over-interpreting low-evidence variants.
• When in doubt, confirm with clinical-grade PGx testing.

Bottom line for practitioners

• Medication Check (PGx) Report = validated, conservative, guideline-aligned.
• DNAmind PGx Report = exploratory, psychiatry-focused, hypothesis-driven.

Both can add value, but only when used within their appropriate clinical context. Questions? Contact support@promicsedge.com.